ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Hansa Biopharma (HNSA.ST)
Hansa Biopharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Nasdaq Stockholm · Sweden
SEK 36.40▼ -0.71%
Prices as of Oct 27, 2026 · SEK
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Hansa Biopharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Hansa Biopharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Hansa Biopharma a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between SEK 32.66 and SEK 39.91; in 9 out of 10, between SEK 27.34 and SEK 47.67. Estimated annual volatility is 55%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- SEK 3.5B
- Market cap (USD)
- $353M
- 52-week high
- SEK 48.22
- 52-week low
- SEK 23.52
- Revenue (12 months)
- SEK 189M
- Gross margin
- 57.2%
- Operating margin
- -334.9%
- Net margin
- 0.0%
- Beta
- 1.66
What this means
ATLAS does not publish a fair value for HNSA.ST right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks HNSA.ST has traded between SEK 23.52 and SEK 48.22. Today it is 24.5% below that high and 55% above its low.
Its beta is 1.66: it tends to move more than the market, both up and down.
About the company
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.
Want to see everything about Hansa Biopharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Hansa Biopharma do?
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.
What is the chance HNSA.ST goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, HNSA.ST ends the month between SEK 32.66 and SEK 39.91.
How big is Hansa Biopharma and what is its P/E ratio?
Hansa Biopharma's market capitalization is SEK 3.5B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is HNSA.ST?
ATLAS estimates annual volatility at 55%. In a typical month, half of the outcomes end between SEK 32.66 and SEK 39.91.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer